Kidney cancer patients denied life-extending drug as NHS watchdog declares it "not cost effective"

Kidney cancer patients denied life-extending drug as NHS watchdog declares it 'not cost effective' NICE says that the NHS should not provide axitinibThe drug can extend the lives of people with advanced kidney cancer but has been deemed not 'cost effective'It works by cutting off the blood supply to the tumour By Jenny Hope Medical Correspondent PUBLISHED: 12:23 GMT, 28 March 2013 | UPDATED: 17:06 GMT, 28 March 2013 Thousands of people with kidney cancer that has spread are to be denied a new pill that could prolong their lives, claim doctors.

Breakthrough as new breast cancer drug increases remission time and reduces side-effects of chemotherapy

Breakthrough as new breast cancer drug increases remission time and reduces side-effects of chemotherapy Drug T-DM1 proven to stall the disease longer than current treatments, says NHS TrustDrug block growth of cancer, then destroys cancer cells from withinCould be available for sufferers within a few years | UPDATED: 15:05 GMT, 4 June 2012 The new treatment uses a two-stage approach to stop cancers growing – and then destroy them from within Medical experts in the UK have made a major breakthrough in their research to keep breast cancer at bay for longer.

Pregnancy is safe for women after breast cancer – and may even have a protective effect

Pregnancy is safe for women after breast cancer – and may even have a protective effect Pregnancy boosts oestrogen levels but did not trigger cancer's return | UPDATED: 10:19 GMT, 21 March 2012 Breast cancer sufferers in remission have been told for the first time it is safe for them to become pregnant.

New drug can slow progress of ovarian cancer by up to six months

New drug can slow progress of ovarian cancer by up to six monthsNew trial of 1,500 women shows Avastindelays the advance of the disease Doctors believe the drug already used to treat colon cancer could become the standard treatment for ovarian cancer A drug can slow down the progress of ovarian cancer – known as the’ silent killer’ – by up to six months, claim researchers. A new trial of 1,500 women shows Avastin delays the advance of the disease by an average of two months, compared with standard chemotherapy. But women with the most aggressive disease got the biggest benefit, with the disease stalled for almost six months

Drug that can keep breast cancer at bay for longer

Breakthrough drug that can keep breast cancer at bay for longer Breakthrough: Women on pertuzumab alongside “wonder” drug Herceptin lived for 18 months without symptoms worsening A breakthrough drug gives women suffering an aggressive form of breast cancer an extra six months before the disease advances. Women on a combination treatment of pertuzumab alongside the ‘wonder’ drug Herceptin lived on average for 18 months without their disease worsening, compared with 12 months for those not taking it